Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Teva and AbCellera agree to collaborate for monoclonal antibodies

Executive Summary

Teva Pharmaceutical Industries Ltd. and AbCellera Biologics Inc. have entered into a collaborative research agreement in which AbCellera will apply its high-throughput single cell antibody platform for the discovery of monoclonal antibodies. The company recently entered into another antibody discovery collaboration with Merck to generate antibodies against an undisclosed target.
Deal Industry
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Concluded
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register